Scientists working for Addex Pharmaceuticals Ltd of Switzerland have reported discovering an apparently novel interaction between two members of the G-protein coupled receptor (GPCR) family which may have implications for the treatment of diabetes.
Scientists working for Addex Pharmaceuticals Ltd of Switzerland have reported discovering an apparently novel interaction between two members of the G-protein coupled receptor (GPCR) family which may have implications for the treatment of diabetes.